DFS according to clinical classification. Using the clinical classification integrating oncogenetics, MRD, and WBC count, 5-year DFS was estimated at 98.3%, 70.9%, and 57.3% in the clinical low-risk group, intermediate-risk group, and high-risk group, respectively.